Finasteride concentrations and prostate cancer risk: Results from the prostate cancer prevention trial

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Chau, Cindy H ^a   Price, Douglas K ^a   Till, Cathee ^b   Goodman, Phyllis J ^b   Chen, Xiaohong ^a   Leach, Robin J ^c   Johnson Pais, Teresa L ^c   Hsing, Ann W ^d   Hoque, Ashraful ^e   Tangen, Catherine M ^b   Chu, Lisa ^d   Parnes, Howard L ^a   Schenk, Jeannette M ^b   Reichardt, Juergen K V ^f   Thompson, Ian M ^c   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d STANFORD CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f JAMES COOK UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE 2; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CLINICAL TRIAL; GENETIC SCREENING; GENETICS; MIDDLE AGED; PROSTATIC NEOPLASMS; STATISTICAL MODEL;

AGED; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP3A; FINASTERIDE; GENETIC TESTING; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 84957573161     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126672     Document Type: Article

References (28)

1. Bruchovsky N, Wilson JD (1968) The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 243:2012-2021. PMID: 4384673
2. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974) Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 186:1213-1215. PMID: 4432067
3. Andersson S, Russell DW (1990) Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. Proc Natl Acad Sci U S A 87:3640-3644. PMID: 2339109
4. Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W, et al. (2007) Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 67:5117-5125. PMID: 17545589
5. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, Nakamura Y, et al. (2008) Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 99:81-86. PMID: 17986282
6. Chaudhary UB, Turner JS (2010) Finasteride. Expert Opin Drug Metab Toxicol 6:873-881. doi: 10. 1517/17425255.2010.495944 PMID: 20536414
7. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. (1992) The Effect of Finasteride in Men with Benign Prostatic Hyperplasia. N Engl J Med 327:1185-1191. PMID: 1383816
8. Stoner E (1992) The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol 147:1298-1302. PMID: 1373779
9. Bull HG, Garcia-Calvo M, Andersson S, Baginsky WF, Chan HK, Ellsworth DE, et al. (1996) Mechanism-Based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor. J Am Chem Soc 118:2359-2365.
10. Yamana K, Labrie F, Luu-The V (2010) Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Invest 2:293-299.
11. Makridakis NM, di Salle E, Reichardt JK (2000) Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics 10:407-413. PMID: 10898110
12. Makridakis N, Akalu A, Reichardt JK (2004) Identification and characterization of somatic steroid 5alpha-reductase (SRD5A2) mutations in human prostate cancer tissue. Oncogene 23:7399-7405. PMID: 15326487
13. Huskey SW, Dean DC, Miller RR, Rasmusson GH, Chiu SH (1995) Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos 23:1126-1135. PMID: 8654202
14. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391. PMID: 11279519
15. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224. PMID: 12824459
16. Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, et al. (1995) Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 16:150-163. PMID: 7540965
17. Chen X, Gardner ER, Price DK, Figg WD (2008) Development and validation of an LC-MS assay for finasteride and its application to prostate cancer prevention trial sample analysis. J Chromatogr Sci 46:356-361. PMID: 18402729
18. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265. PMID: 15297300
19. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. (2002) The structure of haplotype blocks in the human genome. Science 296:2225-2229. PMID: 12029063
20. Gong Z, Kristal AR, Schenk JM, Tangen CM, Goodman PJ, Thompson IM (2009) Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer 115:3661-3669. doi: 10.1002/cncr.24423 PMID: 19598210
21. He BX, Shi L, Qiu J, Tao L, Li R, Yang L, et al. (2011) A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population. Basic Clin Pharmacol Toxicol 108:208-213. doi: 10.1111/j.1742-7843.2010.00657.x PMID: 21199372
22. ∗1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol 64:877-882. doi: 10.1007/s00228-008-0502-x PMID: 18528690
23. ∗1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics 12:977-984. doi: 10.2217/pgs.11.33 PMID: 21635144
24. Schirmer M, Rosenberger A, Klein K, Kulle B, Toliat MR, Nurnberg P, et al. (2007) Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics 8:443-453. PMID: 17465708
25. ∗3 allele: is it really rare? Clin Chem 47:1104-1106. PMID: 11375299
26. Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, et al. (2009) Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 15:4750-4758. doi: 10.1158/1078-0432. CCR-09-0145 PMID: 19584153
27. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, del Alba AG, Climent MA, et al. (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12:1143-1150. doi: 10.1016/S1470-2045 (11) 70266-2 PMID: 22015057
28. Onizuka M, Kunii N, Toyosaki M, Machida S, Ohgiya D, Ogawa Y, et al. (2011) Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant 46:1113-1117. doi: 10.1038/bmt.2010.273 PMID: 21102498